Literature DB >> 16314957

Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies.

Florence Prigent Le Jeune1, François Dubois, Serge Blond, Marc Steinling.   

Abstract

OBJECT: In the follow-up of treated gliomas, CT and MRI can often not differentiate radionecrosis from recurrent tumor. The aim of this study was to assess the interest of functional imaging with (99m)Tc-MIBI SPECT in a large series of 201 examinations.
METHOD: MIBI SPECT were performed in 81 patients treated for brain gliomas. A MIBI uptake index was computed as the ratio of counts in the lesion to counts in the controlateral region. SPECT was compared to stereotactic biopsy in 14 cases, or in the others cases to imaging evolution or clinical course at 6 months after the last tomoscintigraphy Two hundred and one tomoscintigraphies were performed. One hundred and two scans were true positive, 82 scans were true negative. Six scans were false positive (corresponding to 3 patients): 2 patients with an inflammatory reaction after radiosurgery, 1 with no explanation up to now. Eleven scans were false negative (5 patients): 1 patient with a deep peri-ventricular lesion, 2 patients with no contrast enhancement on MRI, 2 patients with a temporal tumor. The sensitivity for tumor recurrence was 90%, specificity 91.5% and accuracy 90.5%. We studied separately low and high grade glioma: sensitivity for tumor recurrence was respectively 91% and 89%, specificity 100% and 83% and accuracy 95% and 87%. MIBI SPECT allowed the diagnose of anaplasic degenerence of low grade sometimes earlier than clinical (5 cases) or MRI signs (7 cases).
CONCLUSIONS: Our results confirm the usefullness of MIBI SPECT in the follow-up of treated gliomas for the differential diagnosis between radiation necrosis and tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314957     DOI: 10.1007/s11060-005-9018-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.

Authors:  J B Bader; S Samnick; J R Moringlane; W Feiden; A Schaefer; S Kremp; C M Kirsch
Journal:  Eur J Nucl Med       Date:  1999-02

2.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

Authors:  C Daumas-Duport; M L Tucker; H Kolles; P Cervera; F Beuvon; P Varlet; N Udo; M Koziak; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

3.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

Authors:  C Daumas-Duport; P Varlet; M L Tucker; F Beuvon; P Cervera; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

4.  Postoperative contrast enhancement in patients with brain tumor.

Authors:  J G Cairncross; J H Pexman; M P Rathbone; R F DelMaestro
Journal:  Ann Neurol       Date:  1985-06       Impact factor: 10.422

5.  Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.

Authors:  D Kahn; K A Follett; D L Bushnell; M A Nathan; J G Piper; M Madsen; P T Kirchner
Journal:  AJR Am J Roentgenol       Date:  1994-12       Impact factor: 3.959

6.  Grading of astrocytomas. A simple and reproducible method.

Authors:  C Daumas-Duport; B Scheithauer; J O'Fallon; P Kelly
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

7.  Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain.

Authors:  N J Patronas; G Di Chiro; R A Brooks; R L DeLaPaz; P L Kornblith; B H Smith; H V Rizzoli; R M Kessler; R G Manning; M Channing; A P Wolf; C M O'Connor
Journal:  Radiology       Date:  1982-09       Impact factor: 11.105

8.  Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy.

Authors:  C Soler; P Beauchesne; K Maatougui; T Schmitt; F G Barral; D Michel; F Dubois; J Brunon
Journal:  Eur J Nucl Med       Date:  1998-12

9.  Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison.

Authors:  L A O'Tuama; S T Treves; J N Larar; A B Packard; A J Kwan; P D Barnes; R M Scott; P M Black; J R Madsen; L C Goumnerova
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

10.  Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi.

Authors:  G Baillet; L Albuquerque; Q Chen; M Poisson; J Y Delattre
Journal:  Eur J Nucl Med       Date:  1994-10
View more
  12 in total

Review 1.  Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.

Authors:  Nishant Verma; Matthew C Cowperthwaite; Mark G Burnett; Mia K Markey
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

Review 2.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

3.  Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results.

Authors:  Amr Amin; Hosna Moustafa; Ebaa Ahmed; Mohamed El-Toukhy
Journal:  J Neurooncol       Date:  2011-09-13       Impact factor: 4.130

Review 4.  Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice.

Authors:  Jacob Ruzevick; Lawrence Kleinberg; Daniele Rigamonti
Journal:  Neurosurg Rev       Date:  2013-11-15       Impact factor: 3.042

Review 5.  Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities.

Authors:  George A Alexiou; Spyridon Tsiouris; Athanasios P Kyritsis; Spyridon Voulgaris; Maria I Argyropoulou; Andreas D Fotopoulos
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

6.  Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response.

Authors:  Spyridon Tsiouris; Ioannis Pirmettis; Theodoros Chatzipanagiotou; Nikolaos Ptohis; Vassilios Papantoniou
Journal:  J Neurooncol       Date:  2007-06-07       Impact factor: 4.130

Review 7.  Progress on the diagnosis and evaluation of brain tumors.

Authors:  Huile Gao; Xinguo Jiang
Journal:  Cancer Imaging       Date:  2013-12-11       Impact factor: 3.909

8.  Comparison of (99m)tc-tetrofosmin and (99m)tc-sestamibi uptake in glioma cell lines: the role of p-glycoprotein expression.

Authors:  George A Alexiou; Xanthi Xourgia; Evrysthenis Vartholomatos; Spyridon Tsiouris; John A Kalef-Ezra; Andreas D Fotopoulos; Athanasios P Kyritsis
Journal:  Int J Mol Imaging       Date:  2014-11-10

9.  Post-treatment Assessment of Glioblastoma Multiforme: Imaging with Fluorodeoxyglucose, Sestamibi, and Choline.

Authors:  Chjoong Howe Alvin Tan; Eik Hock Andrew Tan
Journal:  World J Nucl Med       Date:  2012-01

10.  Assessing response using 99mTc-MIBI early after interstitial chemotherapy with carmustine-loaded polymers in glioblastoma multiforme: preliminary results.

Authors:  D Cecchin; I Schiorlin; A Della Puppa; G Lombardi; P Zucchetta; V Bodanza; M P Gardiman; G Rolma; A C Frigo; F Bui
Journal:  Biomed Res Int       Date:  2014-03-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.